Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

BUY

Well rounded in different health areas.

Wealthica Track your Stocks in your Watch List

BUY

PAST TOP PICK

(Was a top pick on July 17. No change.) Still likes. A core holding.

DON'T BUY

Expensive now. Good long term hold.

TOP PICK

Great price. Should appreciate 15% a year. Good numbers.

BUY

A good long term hold. Good price.

WAIT

Benefiting from weaker US $. Wait for it to reverse its down trend.

BUY

Bullish. International.No generic drug problems. Good cash flow from a lot of coonsumer products.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Great company, but expensive.

BUY

Prefers this and Pfizer over Merk.

BUY

Some good products. Grows well.

BUY

Not cheap. Good stability. Good product development skills.

STRONG BUY

Steady earnings. Demographics on health needs are good.

DON'T BUY

A bit expensive, but a good hold. Buy near $50.

DON'T BUY

Had a nice run. Probably near its top.

Showing 601 to 615 of 626 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)